Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) and Labrys Biologics, Inc., a privately-held development stage biotechnology company focused on treatments for chronic migraine and episodic migraine, announced that Teva has entered into a definitive agreement to acquire Labrys, broadening Teva’s array of biotechnology assets and capabilities. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) net profit margin is 6.80% and weekly performance is -0.71%. On last trading day company shares ended up $51.52. Analysts mean target price for the company is $55.91. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) distance from 50-day simple moving average is 2.46%.
AstraZeneca plc (ADR) (NYSE:AZN) could make its two promising lung cancer drugs available to British patients before completing clinical tests. In that move, the company will be exploiting a window of opportunity that recently opened in the U.K. AstraZeneca plc (ADR) (NYSE:AZN) shares fell -0.83% in last trading session and ended the day on $72.76. AZN Gross Margin is 79.80% and its return on assets is 3.70%. AstraZeneca plc (ADR) (NYSE:AZN) quarterly performance is 7.02%.
Shares of Syngenta AG (NYSE:SYT) have received an average recommendation of “Hold” from the fourteen brokerages that are presently covering the company. Ten research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. Syngenta AG (ADR) (NYSE:SYT) shares moved down -0.26% in last trading session and was closed at $76.83, while trading in range of $76.70-$77.11.Syngenta AG (ADR) (NYSE:SYT) year to date performance is -1.04%.
Bristol-Myers Squibb Co (NYSE:BMY) is receiving a good response for its experimental drug Nivolumab designed to boost the immune system. It is considered as an effective immune therapy to fight cancer. Bristol-Myers Squibb Co (NYSE:BMY) ended the last trading day at $48.98. Company weekly volatility is calculated as 1.74% and price to cash ratio as 11.50. Bristol-Myers Squibb Co (NYSE:BMY) showed a positive weekly performance of 0.18%.
Bayer AG (ADR) (OTCMKTS:BAYRY) Chief Executive Officer Marijn Dekkers will step down at the end of 2016, setting up a contest for the top job at one of Germany’s largest companies. Dekkers’ five-year contract, which expires at the end of 2014, was extended by only two years at the request of the CEO, who cited family reasons, the drugmaker said in a statement. Bayer AG (ADR) (OTCMKTS:BAYRY) On last trading day company shares ended up $143.75.
Leave a Reply